Bahaa Aly v. Valeant Pharmaceuticals Inter

CourtCourt of Appeals for the Third Circuit
DecidedJune 16, 2021
Docket19-3326
StatusPublished

This text of Bahaa Aly v. Valeant Pharmaceuticals Inter (Bahaa Aly v. Valeant Pharmaceuticals Inter) is published on Counsel Stack Legal Research, covering Court of Appeals for the Third Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Bahaa Aly v. Valeant Pharmaceuticals Inter, (3d Cir. 2021).

Opinion

PRECEDENTIAL

UNITED STATES COURT OF APPEALS FOR THE THIRD CIRCUIT _____________

No. 19-3326 _____________

BAHAA ALY; TINA DAVIS; PHILLIP GARLAND; ERINCH OZADA, Appellants, v.

VALEANT PHARMACEUTICALS INTERNATIONAL INC, n/k/a Bausch Health Companies Inc.; J. MICHAEL PEARSON; ROBERT L. ROSIELLO; DEBORAH JORN; ARI S. KELLEN; TANYA CARRO; HOWARD B. SCHILLER ______________

On Appeal from the United States District Court for the District of New Jersey 3:18-cv-17393 District Judge: Hon. Michael A. Shipp _____________

Argued October 20, 2020 ______________ Before: GREENAWAY, JR., COWEN, and FUENTES, Circuit Judges.

(Opinion Filed: June 16, 2021)

Hung G. Ta [ARGUED] JooYun Kim Hung G. Ta, Esq. PLLC 250 Park Avenue, 7th Floor New York, NY 10177

Peter Safirstein Elizabeth Metcalf Safirstein Metcalf LLP 14 Penn Plaza, 9th Floor New York, NY 10122

Counsel for Appellants

Paul C. Curnin Craig S. Waldman [ARGUED] Simpson Thacher & Bartlett LLP 425 Lexington Ave. New York, NY 10017-3954

Richard Hernandez McCarter & English, LLP Four Gateway Center 100 Mulberry Street Newark, NJ 07102

Benjamin Sokoly Winston & Strawn LLP

2 200 Park Avenue New York, NY 10166-4193

Joseph L. Motto Winston & Strawn, LLP 35 W. Wacker Drive Chicago, IL 60601

Matthew Petrozziello Elliot Greenfield Debevoise & Plimpton LLP 919 Third Avenue New York, NY 10022

Barry A. Bohrer Schulte Roth & Zabel LLP 919 Third Avenue New York, NY 10022

Counsel for Appellees

Michael J. Hampson [ARGUED] Mark B. Kramer Lawrence M. Rolnick Rolnick Kramer Sadighi 1251 Avenue of the Americas 18th Floor New York, NY 10020

Sheila A. Sadighi Rolnick Kramer Sadighi 300 Executive Drive Suite 275

3 West Orange, NJ 07052

Counsel of Amicus Appellant

______________

OPINION ______________

FUENTES, Circuit Judge.

This is an appeal from the District Court’s order dismissing the complaint filed by individual shareholders of Valeant Pharmaceuticals Inc. (“Valeant” or the “Company”) as untimely. A class action (the “Class Action”) was filed against Valeant on behalf of investors who purchased its stock between February 23 and October 20, 2015 (the “Relevant Period”).1 Appellants were putative members of that class, but by December 2018, the District Court had still not ruled on class certification. Rather than wait for a decision, Appellants filed the present “opt-out” complaint bringing the same claims in their individual capacities (the “Individual Complaint”). The District Court dismissed the Individual Complaint as untimely under the applicable two-year limitations period, concluding that the tolling doctrine established in American Pipe & Construction Company v. Utah did not apply.2 That doctrine

1 The Class Action, In re Valeant Pharms. Int’l Inc. Sec. Litig., No. 15-cv-7658, was filed in the District Court of New Jersey. 2 414 U.S. 538 (1974).

4 is central to this appeal.

Putative class members may recover as part of the class or seek individual recourse, but they generally cannot do both.3 Complications tend to arise, however, around the class- certification stage. Members may initially intend to proceed as part of a class, but certification may be denied months or years later for reasons outside their control.4 Alternatively, during the pendency of a class action, members may discover that their individual claims are more valuable than those of the class and decide to pursue them in an opt-out complaint even if certification is likely. In either case, members are generally allowed to initiate an individual action, but may run into limitations issues given the delay. This is where American Pipe comes in.

When a class complaint is filed, American Pipe tolls the limitations period governing the individual claims of putative members. In the absence of such a rule, members may feel compelled to file duplicative individual suits bringing the same claims to protect their rights in the event certification is later denied. Otherwise, members would risk allowing their individual limitations periods to expire, potentially leaving them with no recourse in the long run. The doctrine is therefore intended to protect the rights of putative members while

3 See Fed. R. Civ. P. 23(c)(2)(B) (noting the binding effect of a class judgment unless a member requests to be excluded). 4 See Fed. R. Civ. P. 23(b)(3) (setting forth certification criteria).

5 simultaneously avoiding needless identical lawsuits.

On appeal, the parties dispute whether American Pipe tolling applies to individual claims that are filed before a certification decision is made. Appellants argue that the limitations period is tolled regardless of the point at which individual claims are filed. Appellees respond, and the District Court agreed, that members who wish to benefit from American Pipe must wait to file individual claims until after the court rules on certification, which Appellants did not do. For the reasons that follow, we conclude that American Pipe tolled the limitations period for the claims raised in the Individual Complaint. We will vacate and remand for further proceedings. I.5

A.

5 The District Court had jurisdiction under Section 27 of the Exchange Act (15 U.S.C. § 78aa) and 28 U.S.C. § 1331. We have jurisdiction under 28 U.S.C. § 1291. Our review is de novo. Pension Tr. Fund for Operating Eng’rs v. Mortg. Asset Sec. Trans., Inc., 730 F.3d 263, 268 (3d Cir. 2013). Because this is an appeal from a dismissal pursuant to Federal Rule of Civil Procedure 12(b)(6), the facts in this section are as alleged by Appellants. Foglia v. Renal Ventures Mgmt., LLC, 754 F.3d 153, 154 n.1 (3d Cir. 2014) (“We are required to accept as true all allegations in the complaint and all reasonable inferences that can be drawn from them after construing them in the light most favorable to the nonmovant.”) (internal quotation marks omitted).

6 The issue before us relates solely to the timeliness of the Individual Complaint, but we will provide a brief recitation of the facts for context. Valeant develops and manufactures generic pharmaceuticals. Appellants purchased stock in Valeant during the Relevant Period. Prior to their purchase, the Company changed its business model to focus more on acquiring new drugs from other companies rather than developing its own. This approach was intended to significantly cut research-and-development costs and allow Valeant to market its drugs “more efficiently.”6 In the years that followed, Valeant made promising representations about the Company’s financial performance based on its new business model and approach. For instance, investors were assured that Valeant’s superior marketing and leadership resulted in a sales volume that was “greater than price in terms of [Valeant’s] growth,” and that the Company was maintaining “extremely high ethical standard[s]” in the process.7

Free access — add to your briefcase to read the full text and ask questions with AI

Related

American Pipe & Construction Co. v. Utah
414 U.S. 538 (Supreme Court, 1974)
Eisen v. Carlisle & Jacquelin
417 U.S. 156 (Supreme Court, 1974)
Crown, Cork & Seal Co. v. Parker
462 U.S. 345 (Supreme Court, 1983)
Cathy Ann Glater v. Eli Lilly & Co.
712 F.2d 735 (First Circuit, 1983)
In Re WorldCom Securities Litigation
496 F.3d 245 (Second Circuit, 2007)
In Re WorldCom, Inc. Securities Litigation
294 F. Supp. 2d 431 (S.D. New York, 2003)
Thomas Foglia v. Renal Ventures Management
754 F.3d 153 (Third Circuit, 2014)
McKowan Lowe & Co. v. Jasmine, Ltd.
295 F.3d 380 (Third Circuit, 2002)
Mark Wallach v. Eaton Corp
837 F.3d 356 (Third Circuit, 2016)
China Agritech, Inc. v. Resh
584 U.S. 732 (Supreme Court, 2018)
Ari Weitzner v. Sanofi Pasteur Inc
909 F.3d 604 (Third Circuit, 2018)
Harlan v. Veidt
6 Ohio App. 45 (Ohio Court of Appeals, 1915)
Ely v. Borck
7 Ohio App. 49 (Ohio Court of Appeals, 1916)
Phillips v. E.I. Dupont De Nemours & Co.
534 F.3d 986 (Ninth Circuit, 2007)

Cite This Page — Counsel Stack

Bluebook (online)
Bahaa Aly v. Valeant Pharmaceuticals Inter, Counsel Stack Legal Research, https://law.counselstack.com/opinion/bahaa-aly-v-valeant-pharmaceuticals-inter-ca3-2021.